Pomerantz Law Firm Launches Investigation into Theravance Biopharma Investor Claims - Stock Drop Following Negative Study Results Pomerantz LLP is looking into potential investor claims against Theravance Biopharma after the company's disappointing study results caused a significant stock decline.

Pomerantz Law Firm Launches Investigation into Theravance Biopharma Investor Claims - Stock Drop Following Negative Study Results #USA #New_York #Pomerantz_LLP #Theravance_Biopharma #Ampreloxetine

Theravance Biopharma Releases Impressive Q3 2025 Financial Results and Future Plans Theravance Biopharma announces strong Q3 2025 financial results, highlighting record sales of YUPELRI and plans for upcoming pivotal trials.

Theravance Biopharma Releases Impressive Q3 2025 Financial Results and Future Plans #None #Theravance_Biopharma #YUPELRI #Ampreloxetine

Theravance Biopharma Showcases Ampreloxetine Data at International Symposium on Autonomic Nervous System Theravance Biopharma will present impressive findings on ampreloxetine for treating neurogenic orthostatic hypotension at the upcoming International Symposium.

Theravance Biopharma Showcases Ampreloxetine Data at International Symposium on Autonomic Nervous System #United_States #Clinical_Trials #Theravance_Biopharma #Ampreloxetine #Clearwater_Beach

Theravance Biopharma Explores Investment Opportunities at Global Conference Theravance Biopharma, Inc. will present at H.C. Wainwright's annual investment conference, discussing innovations and growth strategies.

Theravance Biopharma Explores Investment Opportunities at Global Conference #United_States #New_York_City #Theravance_Biopharma #YUPELRI #Ampreloxetine

Theravance Biopharma Reaches Enrollment Milestone in Phase 3 Study for Ampreloxetine Targeting Patients with Neurogenic Orthostatic Hypotension Theravance Biopharma has finalized enrollment for its Phase 3 study of ampreloxetine, aimed at treating neurogenic orthostatic hypotension linked to multiple system atrophy, marking a pivotal moment in clinical research.

Theravance Biopharma Reaches Enrollment Milestone in Phase 3 Study for Ampreloxetine Targeting Patients with Neurogenic Orthostatic Hypotension #Ireland #Dublin #Theravance_Biopharma #Ampreloxetine #Neurogenic_Orthostatic_Hypotension

Theravance Biopharma's Second Quarter 2025 Financial Results: A Corporate Update Theravance Biopharma has reported its financial results for the second quarter of 2025, highlighting growth and milestones achieved.

Theravance Biopharma's Second Quarter 2025 Financial Results: A Corporate Update #United_States #Dublin #Theravance_Biopharma #YUPELRI #Ampreloxetine

Theravance Biopharma Engages Investors at Upcoming BioConnect Conference in NYC Theravance Biopharma, Inc. will showcase its innovative therapies during the BioConnect Investor Conference, initiating discussions for future growth.

Theravance Biopharma Engages Investors at Upcoming BioConnect Conference in NYC #United_States #New_York_City #Theravance_Biopharma #YUPELRI #Ampreloxetine

Theravance Biopharma Showcases Promising Results of Ampreloxetine at the International MSA Congress Theravance Biopharma presented encouraging findings on ampreloxetine's effectiveness for neurogenic orthostatic hypotension at the MSA Congress.

Theravance Biopharma Showcases Promising Results of Ampreloxetine at the International MSA Congress #United_States #Boston #Theravance_Biopharma #Ampreloxetine #MSA_Congress

Theravance Biopharma Reports Positive Q1 2025 Financial Performance and Strategic Updates Theravance Biopharma has released its financial results for Q1 2025 alongside significant operational updates on key products, including YUPELRI and ampreloxetine.

Theravance Biopharma Reports Positive Q1 2025 Financial Performance and Strategic Updates #USA #Dublin #Theravance_Biopharma #YUPELRI #Ampreloxetine

Theravance Biopharma to Unveil Critical Phase 3 Findings at Upcoming International MSA Congress 2025 Theravance Biopharma is set to share vital data on ampreloxetine for neurogenic orthostatic hypotension at the 2025 International MSA Congress in Boston.

Theravance Biopharma to Unveil Critical Phase 3 Findings at Upcoming International MSA Congress 2025 #United_States #Theravance_Biopharma #Ampreloxetine #Boston,_Massachusetts #Neurogenic_Orthostatic_Hypotension

Theravance Biopharma's New Research on Ampreloxetine at AAN 2025 Highlights Drug's Potential for Neurogenic Orthostatic Hypotension Theravance Biopharma showcased new findings on ampreloxetine in the context of neurogenic orthostatic hypotension at AAN 2025, highlighting its promising efficacy and safety.

Theravance Biopharma's New Research on Ampreloxetine at AAN 2025 Highlights Drug's Potential for Neurogenic Orthostatic Hypotension #Ireland #Dublin #Theravance_Biopharma #Ampreloxetine #Neurogenic_Orthostatic

Theravance Biopharma to Showcase New Insights on Ampreloxetine for nOH Treatment at Neurology Meeting Theravance Biopharma announces it will present new findings on ampreloxetine, addressing neurogenic orthostatic hypotension at the AAN meeting, April 2025.

Theravance Biopharma to Showcase New Insights on Ampreloxetine for nOH Treatment at Neurology Meeting #United_States #San_Diego #Theravance_Biopharma #Ampreloxetine #nOH

Theravance Biopharma to Showcase Innovations at Oppenheimer Conference in February 2025 Theravance Biopharma is set to present at the upcoming Oppenheimer Healthcare Life Sciences Conference, highlighting its innovative therapies.

Theravance Biopharma to Showcase Innovations at Oppenheimer Conference in February 2025 #Ireland #Dublin #Theravance_Biopharma #YUPELRI #Ampreloxetine